Delisted from NASDAQ in May 2023
OBSV - ObsEva SA
NASDAQ
->
Healthcare
->
Biotechnology
Geneva,
Switzerland
Type: Equity
OBSV price evolution
OBSV
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 30 Dec 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $9.68 | $14.13 | $57.55 | $54.73 |
| Short term investments | ||||
| Net receivables | $0.17 | $0.18 | $0.95 | $3.56 |
| Inventory | ||||
| Total current assets | $11.56 | $48.68 | $64.26 | $63.52 |
| Long term investments | ||||
| Property, plant & equipment | $0.36 | $0.47 | $0.58 | $0.68 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $16.81 | $54.18 | $89.14 | $88.99 |
| Current liabilities | ||||
| Accounts payable | ||||
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $18.84 | $16.33 | $20.78 | $23.51 |
| Long term debt | $32.92 | $33.25 | $25.73 | |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $19.96 | $56.29 | $61.18 | $56.65 |
| Shareholders' equity | ||||
| Retained earnings | -$452.92 | -$446.51 | -$415.54 | -$436.98 |
| Other shareholder equity | $35.06 | $33.24 | $32.2 | |
| Total shareholder equity | -$2.1 | $27.96 | $32.34 | |
| (in millions $) | 30 Dec 2021 | 30 Dec 2020 | 30 Dec 2019 | 30 Dec 2018 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $54.73 | $31.18 | $69.37 | $138.64 |
| Short term investments | ||||
| Net receivables | $3.56 | $0.4 | $1.04 | $0.89 |
| Inventory | ||||
| Total current assets | $63.52 | $36.97 | $74.77 | $145.24 |
| Long term investments | ||||
| Property, plant & equipment | $0.68 | $1.58 | $2.29 | $0.32 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $28.48 | $29.17 | $22.2 | |
| Total investments | ||||
| Total assets | $88.99 | $65.45 | $103.94 | $167.44 |
| Current liabilities | ||||
| Accounts payable | $10.76 | $8.43 | $2.77 | |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $23.51 | $21.7 | $19.47 | $16.93 |
| Long term debt | $25.73 | $25.3 | $24.92 | |
| Total noncurrent liabilities | $35.39 | $35.52 | $3.6 | |
| Total debt | ||||
| Total liabilities | $56.65 | $57.09 | $54.99 | $20.52 |
| Shareholders' equity | ||||
| Retained earnings | -$436.98 | -$379.39 | -$297.41 | -$183.93 |
| Other shareholder equity | $32.2 | $26.35 | $21.91 | $12.86 |
| Total shareholder equity | $32.34 | $8.35 | $48.95 | $146.92 |
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 31 Jan 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3.71 | |||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $4.34 | |||
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0.05 | |||
| Interest expense | $0.39 | |||
| Net income | ||||
| Net income | -$12.06 | |||
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2022 | 30 Dec 2020 | 30 Dec 2019 | 30 Dec 2018 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $67.54 | $88.05 | $62.87 | |
| Selling, general & administrative | $12.18 | $19.06 | $14.3 | |
| Total operating expenses | $79.7 | $107.09 | $77.15 | |
| Operating income | -$79.7 | -$107.09 | -$77.15 | |
| Income from continuing operations | ||||
| EBIT | -$79.7 | -$107.09 | -$77.15 | |
| Income tax expense | $0.03 | $0.07 | -$0.04 | |
| Interest expense | -$2.7 | -$1.19 | -$1.19 | |
| Net income | ||||
| Net income | -$82.97 | -$108.79 | -$76.72 | |
| Income (for common shares) | -$82.97 | -$108.79 | -$76.72 | |
| (in millions $) | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 | 30 Dec 2021 |
|---|---|---|---|---|
| Net income | -$20.05 | |||
| Operating activities | ||||
| Depreciation | $0.12 | |||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$12.76 | |||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | $5.68 | $5.68 | $5.69 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$1.93 | |||
| Total cash flows from financing | -$19.32 | $11.03 | $12.19 | $3.85 |
| Effect of exchange rate | -$0.34 | -$0.34 | $0.19 | $0.75 |
| Change in cash and equivalents | -$45.05 | -$9.61 | $2.82 | -$8.15 |
| (in millions $) | 30 Dec 2021 | 30 Dec 2020 | 30 Dec 2019 | 30 Dec 2018 |
|---|---|---|---|---|
| Net income | -$58.38 | -$82.97 | -$108.79 | -$76.72 |
| Operating activities | ||||
| Depreciation | $0.74 | $0.72 | $0.74 | $0.11 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$70.3 | -$70.77 | -$90.61 | -$63.94 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.01 | -$0.05 | -$0.19 |
| Investments | ||||
| Total cash flows from investing | $22.19 | -$0.01 | -$5.05 | -$0.27 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | ||||
| Net borrowings | -$2.44 | -$0.63 | $24.16 | $24.16 |
| Total cash flows from financing | $71.1 | $32.25 | $26.63 | $91.65 |
| Effect of exchange rate | $0.56 | $0.34 | -$0.24 | $0.36 |
| Change in cash and equivalents | $23.55 | -$38.19 | -$69.27 | $27.8 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 104.02M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | -81.53% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.09 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.75 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.61 |
| Quick ratio | N/A |